samedan logo
 
 
spacer
home > epc > spring 2007 > easy to swallow
PUBLICATIONS
European Pharmaceutical Contractor

Easy to Swallow

Therapeutic proteins are one of the most important and rapidly growing segments of the pharmaceutical market, with annual sales of over US$35 billion in 2005. Paul Martin of Nautilus Biotech reports on recent developments in oral drug delivery of therapeutic proteins

Despite the increasing predominance of therapeutic proteins on the market, producers of first generation protein drugs currently face a number of important problems. One example is patent expiries on several blockbuster products and the competition from small molecule alternatives and biogenerics. In addition, the need for better clinical performance, as well as product life cycle management, is motivating the search for products with improved characteristics (for example, longer half-life in serum) as well as alternatives to injection as the main route of administration.

ESTABLISHED STRATEGIES FOR ORAL DELIVERY

In order to develop new routes of administration, heavy investment has been made in pulmonary, nasal and oral drug delivery. In particular, oral delivery of therapeutic proteins has long been a major objective of the biotech industry, as this would significantly increase the ease of administration, and would allow more tailored dosing regimes. These in turn could greatly improve patient compliance. However, effective oral delivery of a protein will require overcoming a number of major challenges, including: the need to ensure the protein is protected from degradation by the specific proteases encountered throughout the oral delivery pathway (for instance, oral mucosa, saliva, stomach and intestine), as well as the low pH in the stomach and the need for epithelial transport from the intestinal lumen into the blood (1). At the same time, any drug that enters the bloodstream will need to maintain a good PK profile (that is, half-life in serum).


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Dr Paul Martin is Co-Founder and Vice President of Strategy at Nautilus Biotech. Paul has a degree in Zoology from the University of Cambridge and worked as a Postgraduate Researcher in mouse developmental biology, before taking a PhD in Science and Technology Studies at the University of Sussex. Paul is also Associate Professor of Science and Technology studies at the University of Nottingham.
spacer
Dr Paul Martin
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Evolution Summit 2010

27-29 October 2010, Montreux, Switzerland

Amidst attrition challenges and pressures from stakeholders, the laurels are up for grabs for the next leaders in drug development. While the industry is struggling to achieve financial sustainability and operational viability, it is awaiting the leadership of a new bold visionary who will bring fundamental innovation to overhauling the research approaches of the past. When gearing up for the future, pharmaceutical and biopharmaceutical companies continue securing long-lasting lucrative partnerships along their value chains. Incorporating novel development paradigms and improving internal decision-making pave the way to shorter timelines and growing profit margins.
More info >>

 
News and Press Releases

The highest performance in its class

Shimadzu, one of the worldwide leading manufacturers in analytical instrumentation, has launched a new GCMS-QP2010 Ultra gas chromatograph mass spectrometer (GC/MS) offering the highest performance in its class. It provides fast data measurement speed with five times higher sensitivity than previous models. In addition to improving laboratory productivity for high-speed analysis, it also offers improved applicability for comprehensive two-dimensional gas chromatography (GCxGC), which can achieve ultra high separation. It is also the first GC/MS system to have environmentally friendly features for saving power consumption and carrier gas.
More info >>

 

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement